Background: Automatic office blood pressure measurement (AOBPM) in the waiting room could improve the performance of diagnosing hypertension without requiring an isolated room to carry out exploration. Methods: In a cross‐sectional study, we compared the performance to diagnose and phenotyping hypertension by 3 methods of blood pressure measurements, standard office blood pressure, unattended AOBPM in an isolated room or in an office waiting room AOBPM, compared with daytime ambulatory blood pressure measurement (daytime ambulatory blood pressure monitoring) from a 24‐hour ambulatory blood pressure monitoring as a reference. The cutoff values for hypertension and validation for waiting room or isolated room AOBPM were performed by receiver operating characteristic curves and Bland–Altman plots compared with daytime ambulatory blood pressure monitoring. Results: Out of the 548 participants recruited, 349 (64%) had hypertension, while 199 (36%) were being studied for a diagnosis of hypertension. Waiting room AOBPM and unattended AOBPM stratified hypertension status in a comparable way (n=398; 73% [95% CI, 69%–76%; and n=417; 75% [95% CI, 72%–79%] participants, respectively), and both methods stratified better hypertension status than standard office blood pressure measurement did (n=338; 62% [95% CI, 57%–65%]). Overall, the diagnostic accuracy for white coat syndrome was better for waiting room AOBPM, while for masked hypertension it was by unattended AOBPM (80% [95% CI, 77%–83%] versus 87% [95% CI, 83%–89%] and 88% 95% CI, 85%–90%] versus 73% [95% CI, 69%–76%], respectively). Conclusions: To assess hypertension status, waiting room AOBPM is equivalent to unattended AOBPM in an isolated room and both better than standard office blood pressure measurement. The detection of hypertension phenotypes differs depending on the site of the measurement, waiting room or isolated room. Registration: URL: https://clinicaltrials.gov ; unique identifier: NCT06198855.

BACKGROUND Detecting total cholesterol in dried blood spots could aid in identifying individuals with a high likelihood of familial hypercholesterolemia and could be used as a screening measure. This study aims to assess the diagnostic accuracy of dried blood spots on Whatman 903 paper cards using a manual enzymatic technique. METHODS A total of 394 samples collected as serum and dried blood spots were compared. Cholesterol was determined in serum using the automated reference method, while cholesterol on paper was measured using a manual enzymatic method. Within- and between-day diagnostic variability were analyzed. The correlation between both methods was assessed using Passing-Bablok regression and Bland-Altman plot. Internal validation of our correlation formula was performed on 149 samples, along with external validation of the formula proposed by Corso et al. RESULTS The within- and between-day coefficient of variation was found to be lower than 10.14% and 14.09%, respectively. Method comparison yielded an area under the curve of 0.976, with a standard error of 0.009. Passing-Bablok regression indicated a precision of 0.803 and an accuracy of 0.96. Internal validation precision was measured at 0.716. Regarding internal validation, calculated cholesterol with our regression line did not differ from serum cholesterol analysis, while significant differences were observed in calculated cholesterol levels using the external formula. CONCLUSIONS Total cholesterol analysis in dot blood spots demonstrates high precision and reproducibility. This method reliably enables the incorporation of this biological marker into neonatal screening for familial hypercholesterolemia detection.

Subclinical atrial fibrillation is a leading underlying cause of cryptogenic stroke. Early prolonged cardiac monitoring is recommended, yet timely access is often limited. We evaluated the performance and therapeutic implications of prolonged cardiac monitoring using the NUUBO^® wearable system in routine clinical practice, where initiating monitoring within the first 30 days after stroke was uncommon. This single-center ambispective study (2018–2024), included consecutive adults with cryptogenic ischemic stroke who underwent 15–28 days of cardiac monitoring with the NUUBO^® textile wearable system. The primary outcome was atrial fibrillation detection. Associations between atrial fibrillation and baseline or clinical characteristics were examined using multivariate logistic regression. Monitoring adherence and treatment changes were also recorded. 352 patients (99.4%) completed all the monitoring. Atrial fibrillation was detected in 38 patients (10.8%), leading to anticoagulation in 36 (94.7%). Advanced age (median 73 (interquartile range 69–80) vs. 66 (57–74) years; p < 0.001) and large-vessel occlusion at stroke onset (31.6% vs. 17.2%; p = 0.047) were independently associated with atrial fibrillation. Patients monitored within < 30 days, between 31 and 90 days, 91–365 days, or after 12 months of the index event had atrial fibrillation detection rates (9.5%-11.6%). NUUBO^® proved useful for detecting atrial fibrillation after cryptogenic ischemic stroke. Atrial fibrillation was detected even among patients monitored late (9.5–11.6%). These findings provide a useful starting point for further studies aimed at confirming whether significant atrial fibrillation detection rates can be achieved with delayed prolonged cardiac monitoring after cryptogenic ischemic stroke.